---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-133076"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2024-12-04T23:59:59+00:00"
generated_at: "2026-05-29T08:21:38.684688+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# EyePoint dosed first patient in second Phase 3 wet AMD trial (LUCIA); topline data expected 2026

## Summary
- First patient dosed in LUCIA, the second global Phase 3 trial of DURAVYU (vorolanib Durasert E) for wet AMD.
- LUCIA follows LUGANO trial; both are randomized, double-masked, non-inferiority vs aflibercept with ~400 patients each.
- Primary endpoint: average change in BCVA at weeks 52 and 56; re-dosing every six months.
- Topline data from Phase 3 pivotal program anticipated in 2026; over 240 global sites committed.
- CEO cites robust interest and strong balance sheet; LUGANO enrollment exceeded expectations.

## SEC filing metadata
- accession: 0000950170-24-133076
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2024-12-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017024133076/0000950170-24-133076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017024133076/eypt-20241204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-133076
- JSON: https://secwatch.observer/filing/0000950170-24-133076.json
- Plain text: https://secwatch.observer/filing/0000950170-24-133076.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.